Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.

Glassman PM, Balthasar JP

DOI: 10.7497/j.issn.2095-3941.2014.01.002
Published: 2014 Mar
Container: Cancer biology & medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.7497/j.issn.2095-3941.2014.01.002,
  title = {Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.},
  author = {Glassman PM and Balthasar JP},
  year = {2014},
  journal = {Cancer biology \& medicine},
  doi = {10.7497/j.issn.2095-3941.2014.01.002},
  url = {https://doi.org/10.7497/j.issn.2095-3941.2014.01.002}
}

RIS

TY  - JOUR
TI  - Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
AU  - Glassman PM
AU  - Balthasar JP
PY  - 2014
JO  - Cancer biology & medicine
DO  - 10.7497/j.issn.2095-3941.2014.01.002
UR  - https://doi.org/10.7497/j.issn.2095-3941.2014.01.002
ER  -

APA

PM, G., & JP, B. (2014). Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.. Cancer biology & medicine. https://doi.org/10.7497/j.issn.2095-3941.2014.01.002

Source records

pubmed · retrieved 2026-09-26T00:42:23.912Z